AI Article Synopsis
- PDAC is a major cause of cancer-related deaths, and despite progress in understanding its causes, treatment outcomes are still unsatisfactory.
- A meta-analysis was conducted to investigate the link between SMAD4 loss and its clinical implications in PDAC, involving an extensive literature review and data analysis.
- Results showed a significant increase in SMAD4 protein loss in PDAC compared to nonmalignant tissue, which is associated with poorer overall survival, marking SMAD4 as a potential diagnostic biomarker for PDAC.
Article Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer mortality. Although advances have been made in understanding the pathogenesis of PDAC, the outcome still remains poor. The aim of this study is to conduct a meta-analysis to evaluate the precise association between SMAD4 loss and clinicopathological significance in PDAC. A literature search was made in PubMed, Web of Science, Google scholar, and EMBASE for related publications. The data were extracted and assessed by two reviewers independently. Analysis of pooled data was performed, Odds Ratio or Hazard Ratio with corresponding confidence intervals was calculated and summarized. 12 relevant articles were included for full review in detail and meta-analysis. The frequency of SMAD4 protein loss was significantly increased in PDAC than in nonmalignant pancreatic tissue, Odd Ratio was 0.05 with 95% confidence interval 0.01-0.23, p<0.0001. SMAD4 loss was significantly associated with poor overall survival in patients with PDAC, Hazard Ratio was 0.61 with 95% confidence interval 0.38-0.99, p=0.05. SMAD4 loss was not correlated with the size, grades, and lymph node metastasis of PDAC. In conclusion, SMAD4 is a biomarker for the diagnosis of PDAC. SMAD4 loss is significantly related to poor prognosis in patients with PDAC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369995 | PMC |
| http://dx.doi.org/10.18632/oncotarget.14335 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
D-loop mutations in mitochondrial DNA are a risk factor for chemotherapy resistance in esophageal cancer.
Sci Rep
December 2024
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, 2-2-E2, Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Esophageal cancer is a highly aggressive disease, and acquired resistance to chemotherapy remains a significant hurdle in its treatment. mtDNA, crucial for cellular energy production, is prone to mutations at a higher rate than nuclear DNA. These mutations can accumulate and disrupt cellular function; however, mtDNA mutations induced by chemotherapy in esophageal cancer remain unexplored.
View Article and Find Full Text PDFCollaborative machine learning-guided overall survival prediction of oral squamous cell carcinoma.
Acta Otolaryngol
December 2024
Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Background: There is a lack of prognosticators of overall survival (OS) for Oral Squamous Cell Carcinoma (OSCC).
Objectives: We examined collaborative machine learning (cML) in estimating the OS of OSCC patients. The prognostic significance of the clinicopathological parameters was examined.
Pan-cancer analysis shows that BCAP31 is a potential prognostic and immunotherapeutic biomarker for multiple cancer types.
Front Immunol
December 2024
Department of Otolaryngology, the Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu, China.
Background: B-cell receptor-associated protein 31 (BCAP31) is a widely expressed transmembrane protein primarily located in the endoplasmic reticulum (ER), including the ER-mitochondria associated membranes. Emerging evidence suggests that BCAP31 may play a role in cancer development and progression, although its specific effects across different cancer types remain incompletely understood.
Methods: The raw data on BCAP31 expression in tumor and adjacent non-tumor (paracancerous) samples were obtained from the Broad Institute Cancer Cell Line Encyclopedia (CCLE) and UCSC databases.
Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.
BMC Womens Health
December 2024
Department of Blood Transfusion, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
Objective: This study aimed to analyse the correlation between the expression of cell proliferation-associated antigen (Ki-67), cell cycle protein-dependent kinase 4 (CDK4), epidermal growth factor receptor (EGFR), tumour-infiltrating lymphocytes (TILs) and circulating tumour DNA (ctDNA) with the outcome and prognosis of patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT).
Methods: We retrospectively analysed the clinicopathological data of 231 patients with BC who underwent preoperative NACT at XX Hospital between 1 January 2018 and 31 December 2021. Logistic regression models were used to analyse factors influencing NACT efficacy.
The deep learning radiomics nomogram helps to evaluate the lymph node status in cervical adenocarcinoma/adenosquamous carcinoma.
Front Oncol
December 2024
Department of Radiology, Jinshan Hospital, Fudan University, Shanghai, China.
Objectives: The accurate assessment of lymph node metastasis (LNM) can facilitate clinical decision-making on radiotherapy or radical hysterectomy (RH) in cervical adenocarcinoma (AC)/adenosquamous carcinoma (ASC). This study aims to develop a deep learning radiomics nomogram (DLRN) to preoperatively evaluate LNM in cervical AC/ASC.
Materials And Methods: A total of 652 patients from a multicenter were enrolled and randomly allocated into primary, internal, and external validation cohorts.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!